|Other Names||Dihydropyrimidinase, DHP, DHPase, Dihydropyrimidine amidohydrolase, Hydantoinase, DPYS|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13434b was selected from the C-term region of DPYS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6- dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.|
|Tissue Location||Liver and kidney.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Dihydropyrimidinase catalyzes the conversion of5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism.Dihydropyrimidinase is expressed at a high level in liver andkidney as a major 2.5-kb transcript and a minor 3.8-kb transcript.Defects in the DPYS gene are linked to dihydropyrimidinuria.
Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)
If you have any additional inquiries please email technical services at email@example.com.